Singapore markets closed
Explore/

The Fight Against COVID19

The Fight Against COVID19

21.23k followers14 symbols Watchlist by TREA

Follow this list to discover and track the stock of publicly traded companies with COVID-19 related treatment and healthcare plans.

Curated by TREA

TREA analyzes over 100 million data points, interactions, relationships on company research and development activities, allowing investors to quickly gain insight without having to go through complex regulatory filings. Primary data sources include: FDA (Food and Drug Administration), NIH (National Institutes of Health), USPTO (US Patent and Trademark Office). The search parameters for generating this watchlist were (1) Above sector average Innovation Index score, (2) IP history at least 5 years (3) COVID19 (4) 2019-nCov (5) SARS-CoV-2 among others.

Performance

WatchlistChange today1-month return1-year returnTotal return
The Fight Against COVID19-1.91%---
^GSPC-1.31%+0.18%+33.63%+4380.05%

14 symbols

SymbolCompany nameLast priceChange% changeMarket timeVolumeAvg vol (3-month)Market cap
JNJJohnson & Johnson161.98-3.24-1.96%4:00 pm GMT-412.99M7.16M426.56B
PFEPfizer Inc.38.81-0.67-1.70%4:02 pm GMT-433.21M26.94M217.25B
ABBVAbbVie Inc.113.12-1.78-1.55%4:03 pm GMT-46.95M6.62M199.79B
SNYSanofi52.86-0.38-0.71%4:00 pm GMT-45.68M1.32M133.96B
GSKGlaxoSmithKline plc39.84-0.73-1.80%4:00 pm GMT-49.92M4.64M100.23B
GILDGilead Sciences, Inc.66.61-0.61-0.91%4:00 pm GMT-410.09M7.18M83.54B
MRNAModerna, Inc.199.19-3.28-1.62%4:00 pm GMT-46.66M9.32M79.98B
REGNRegeneron Pharmaceuticals, Inc.537.92+1.91+0.36%4:00 pm GMT-4914.79k815.33k57.31B
TAKTakeda Pharmaceutical Company Limited16.55-0.36-2.13%4:00 pm GMT-44.43M2.42M52.79B
BNTXBioNTech SE212.42-1.78-0.83%4:00 pm GMT-42.26M3.04M51.30B
NVAXNovavax, Inc.174.41-5.48-3.05%4:00 pm GMT-42.88M3.75M12.92B
VIRVir Biotechnology, Inc.46.15+2.33+5.32%4:00 pm GMT-41.77M689.34k6.00B
INOInovio Pharmaceuticals, Inc.8.49-0.33-3.74%4:00 pm GMT-45.60M8.39M1.78B
  • How This Pharma Company Can Benefit From Its Competitors
    Motley Fool

    How This Pharma Company Can Benefit From Its Competitors

    The race is on among pharmaceutical companies to obtain approval from the U.S. Food and Drug Administration (FDA) for new products serving the atopic dermatitis (AD, otherwise known as severe and chronic eczema) market. One of those companies, Incyte (NASDAQ: INCY), is coming off successful phase 3 trials of its ruxolitinib cream, but is now facing challenges brought on by delays in FDA approval.

  • Reuters

    Swiss to start inoculating youngsters against COVID-19 as early as next week

    Switzerland plans to allow 12- to 15-year olds to receive vaccinations against COVID-19 as soon as next week, government vaccine chief Christoph Berger told Swiss newspaper NZZ in an interview published on Sunday. "Young people who want to be vaccinated should be given the opportunity," Berger told NZZ, adding the government's approval was expected to be communicated next week. "For those with pre-existing conditions or those in contact with immunocompromised individuals who are at risk, vaccination makes sense," he said, adding that - unlike for older populations - it would not be necessary to target a vaccination rate for the 12- to 15-year old population.

  • Reuters

    Israel says COVID-19 vaccines rejected by Palestinians were safe

    COVID-19 vaccines delivered by Israel and then rejected by the Palestinian Authority (PA) over their expiration date were fine, the Israeli health ministry said on Saturday. Israel and the PA on Friday announced a vaccine swap deal that would have seen Israel send up to 1.4 million doses of the vaccine made jointly by Pfizer (PFE.N) and BioNTech (22UAy.DE) to the PA in exchange for receiving a reciprocal number of doses later this year. But soon after the announcement, the PA cancelled the deal and said it had sent an initial shipment of around 90,000 doses back to Israel.